Ipamorelin vs GHRP-2

Dose, schedule, route and approval status side by side.

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.

	Ipamorelin	GHRP-2
Status	Not approved	Not approved
Also known as	–	pralmorelin
Typical dose	100–300 mcg	100–300 mcg
How often	Daily, 1–3 times	Daily, 1–3 times
Schedule	One to three times daily, commonly before bed.	One to three times daily.
Daily equivalent	100–900 mcg/day	100–900 mcg/day
Route	Subcutaneous	Subcutaneous
Duration	8–12 weeks reported	8–12 weeks reported
Notes	Growth hormone secretagogue. Reached Phase 2 for post-surgical bowel recovery but was not approved.	Used in Japan as a single-dose diagnostic test for growth hormone deficiency, not as a treatment. Increases appetite and cortisol.

This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the Ipamorelin and GHRP-2 pages.

Advertise here